Defence Therapeutics 주식 가격. DTC - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

가격

1.25

매수가

1.18

매도가

1.25

거래량

136,930

1.19 일간 변동폭 1.25

0.48 52주 범위 2.10

전일 종가

1.16

개장가

1.20

최근 거래 시간

2800

1.25

마지막 거래 시간

평균 볼륨(3m)

54,232

재정 규모

VWAP

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER Vancouver, BC, Canada, February 16th, 2022...

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to...

DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

Vancouver, BC, Canada -- November 30th 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. (CSE: DTC; FSE: DTC; USOTC:...

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER Vancouver, BC, Canada...

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS Vancouver, BC, Canada, November 9th, 2021 -- InvestorsHub NewsWire...

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN...

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0.14	12.6126126126	1.11	1.25	1.04	61440	1.13121581	CS
4	0.58	86.5671641791	0.67	1.28	0.67	104071	1.05001882	CS
12	0.73	140.384615385	0.52	1.28	0.49	54232	0.89582082	CS
26	0.52	71.2328767123	0.73	1.28	0.48	38713	0.78324839	CS
52	-0.66	-34.554973822	1.91	2.1	0.48	36550	0.96085354	CS
156	-3.24	-72.1603563474	4.49	4.85	0.48	22543	1.88154091	CS
260	-0.5	-28.5714285714	1.75	8.15	0.48	20617	2.33227476	CS

DTC - Frequently Asked Questions (FAQ)

What is the current Defence Therapeutics share price?

The current share price of Defence Therapeutics is $ 1.25

What is the 1 year trading range for Defence Therapeutics share price?

Defence Therapeutics has traded in the range of $ 0.48 to $ 2.10 during the past year

가장 활성
% 상승자
% 패자

기호	가격	볼륨
MJRXGlobal Health Clinics Ltd	$ 0.02 (100.00%)	1,000
BLRBlackhawk Growth Corp	$ 0.01 (100.00%)	14k
GRUVProtium Clean Energy Corp	$ 0.035 (75.00%)	3.27M
ADPAdelphi Metals Inc	$ 0.20 (73.91%)	2.02k
GRHKGreenhawk Resources Inc	$ 0.025 (66.67%)	2.09M
WBGDWaraba Gold Limited	$ 0.005 (-50.00%)	9k
CVGRCity View Green Holdings Inc	$ 0.005 (-50.00%)	51k
CATCAT Strategic Metals Corporation	$ 0.005 (-50.00%)	52k
ASTIAquarius Surgical Technologies Inc	$ 0.01 (-50.00%)	36k
URMFirst American Uranium Inc	$ 0.015 (-40.00%)	6.84k
QIMCQuebec Innovative Materials Corp	$ 0.23 (35.29%)	6.87M
AIMLAl ML Innovations Inc	$ 0.06 (-14.29%)	3.84M
GRUVProtium Clean Energy Corp	$ 0.035 (75.00%)	3.27M
GRHKGreenhawk Resources Inc	$ 0.025 (66.67%)	2.09M
SANUSanu Gold Corp	$ 0.255 (8.51%)	1.9M

Man6677 3 년 전

Why are there no trades here ?

Thank you !

Great news today !

👍️0

newspopper 3 년 전

Get in KITL .08-.10 news will be poppin

👍️0

newspopper 3 년 전

Need more volume for Poppin action

👍️0

newspopper 3 년 전

Looking for FDA Poppin news

👍️0

newspopper 3 년 전

KITL news going to be poppin

👍️0

GOLDBUFFALO 3 년 전

Seems to be a very interesting stock.

👍️0

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Defence Therapeutics Inc (DTC)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

DTC 최신 뉴스

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA

DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER

DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS

DTC - Frequently Asked Questions (FAQ)

이동자

DTC Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Defence Therapeutics Inc (DTC) 시세

Defence Therapeutics Inc (DTC)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

DTC 최신 뉴스

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA

DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER

DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS

DTC - Frequently Asked Questions (FAQ)

이동자

DTC Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거